missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ ACVR1B Polyclonal Antibody
Description
A suggested positive control is human kidney tissue lysate. PA5-20596 can be used with blocking peptide PEP-0716.
ACVR1B is a serine/threonine kinase involved in signal transduction and cellular communication. Several truncated ACVR1B isoforms have been reported to be exclusively expressed in human pituitary tumors. Mutations of ACVR1B have been observed in pancreatic adenocarcinomas. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. ACVR1B encodes activin A type IB receptor, composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.
Specifications
Specifications
| Antigen | ACVR1B |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% sodium azide |
| Gene | ACVR1B |
| Gene Accession No. | P36896, Q61271 |
| Gene Alias | 6820432J04; activin A receptor type 1B; activin A receptor type IB; activin A receptor, type 1B; activin A receptor, type IB; activin A receptor, type II-like kinase 4; activin receptor type IB; Activin receptor type-1B; activin receptor-like kinase 4; ACTRI; ActRIB; ActR-IB; ACVR1A; Acvr1b; ACVRLK2; ACVRLK4; ALK2; Alk4; ALK-4; FOP; Serine/threonine-protein kinase receptor R2; SKR1; SKR2; TSRI |
| Gene Symbols | ACVR1B |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?